Guadecitabine vs TC in relapsed/refractory AML after intensive chemotherapy: randomized phase 3 ASTRAL-2 trial

Gail J. Roboz,Guillermo Sanz,Elizabeth A. Griffiths, Karen Yee,Hagop Kantarjian,Christian Recher,Michael T. Byrne, Elżbieta Patkowska,Hee-Je Kim,Xavier Thomas,Ine Moors,Wendy Stock,Árpád Illés,Pierre Fenaux,Yasushi Miyazaki,Takahiro Yamauchi, Casey L. O'Connell,Yong Hao, Harold N. Keer,Mohammad Azab

Blood advances（2024）

引用 0|浏览16

暂无评分

摘要

•There was no clear survival benefit for guadecitabine over standard-of-care in patients with relapsed/refractory AML.•Guadecitabine produced higher clinical response rates, with potential survival benefit in several prespecified subgroups.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要